The impact of primary tumor location (PTL) and age on the risk of developing noncolonic second primary malignancy (SPM) in colon cancer (CC) patients (PTS).

Authors

null

Charles Chu

University of California San Francisco, San Francisco, CA

Charles Chu , Albert Y. Lin

Organizations

University of California San Francisco, San Francisco, CA, Palo Alto VA, Palo Alto, CA

Research Funding

No funding received
None

Background: Colon cancer remains one of the leading causes of cancer death worldwide. There has been a renewing interest in the role of PTL (right- or RS vs. left-sided or LS) in CC for their differences in biology, prognostic and predictive features. Given the increasing incidence of early-onset (age 20-49) CC, coupled with their longer life expectancy, we seek to examine the effects of PTL and age in the development of SPM in a population-based cohort. Methods: Surveillance, Epidemiology, and End Results (SEER) Program data were queried to identify CC PTS diagnosed between 1973-2015 with complete follow-up information and available data on SPM. Using SEER*Stat, we calculated standardized incidence ratios (SIRs) -- the ratio of observed to expected cases of SPM based on incidence data in the general US population and compared by PTL (RS vs. LS) and age of diagnosis (20-49 vs. >49). Results: A total of 269,442 (RS/LS=46.4%/53.6%) CC PTS were obtained. Overall RS, compared with LS, CC PTS have a higher likelihood of developing SPM in all sites (OR: 1.09, 95% CI: 1.08- 1.11 vs. 1.03, 1.02-1.04). RS CC PTS and age 20-49 group, compared with other subgroups, has a much greater likelihood of being diagnosed with the following SPM:small intestine, urinary tract, bile duct, gynecologic (GYN), and stomach cancers, as shown in the Table below. Conclusions: Our results show that the increased risk in non-colonic SPMs in CC PTS is associated with RS CC and age less than 49, suggesting the implications on survivorship care and surveillance of SPMs. Furthermore, there may be a possible overlap with Lynch syndrome in these PTS with SPM given the overlap in the presentation of cancer patterns and early-onset of CC, suggesting the indication for MMR testing.

SPM Age RS
LS
SIR 95% CI SIR 95% CI
Small intestine 20-49 16.89 12.69 22.04 7.25 5.13 9.95
> 49 3.49 3.07 3.97 2.47 2.14 2.83
Urinary tract cancer 20-49 10.17 6.03 16.07 4.70 2.63 7.76
> 49 1.5 1.29 1.79 0.99 0.80 1.20
Bile duct cancer 20-49 5.49 3.20 8.79 2.89 1.65 4.70
> 49 1.32 1.12 1.54 1.22 1.05 1.42
GYN cancer 20-49 4.31 3.47 5.29 1.91 1.51 2.37
> 49 1.19 1.09 1.30 1.08 0.98 1.18
Stomach 20-49 3.48 2.42 4.84 1.97 1.35 2.76
> 49 1.18 1.08 1.30 1.13 1.03 1.23

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Prevention, Screening, and Hereditary Cancers

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 67)

Abstract #

67

Poster Bd #

C17

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Relative and collective contribution of liver and bile duct cancer risk factors among minority groups in California.

First Author: M. Cecilia Monge B.

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Histopathologic and genomic profile characteristics of biliary cancers related to pancreaticobiliary maljunction.

First Author: Shodai Tohyama

First Author: Eric Adjei Boakye